ITM nears FDA decision after positive COMPETE radiopharmaceutical trial
ITM’s lutetium-177 edotreotide extended median progression-free survival to 23.9 months versus 14.1 months with everolimus, strengthening its regulatory and commercial case in advanced neuroendocrine tumours.